• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Personalis Inc.

    2/27/25 5:27:26 PM ET
    $PSNL
    Medical Specialities
    Health Care
    Get the next $PSNL alert in real time by email
    S-8 1 d925869ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 27, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    PERSONALIS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   27-5411038
    (State or other jurisdiction of
    Incorporation or organization)
      (I.R.S. Employer
    Identification No.)

    6600 Dumbarton Circle

    Fremont, California 94555

    (650) 752-1300

    (Address of principal executive offices) (Zip code)

    2019 Equity Incentive Plan

    2019 Employee Stock Purchase Plan

    (Full titles of the plans)

     

     

    Christopher Hall

    President and Chief Executive Officer

    Personalis, Inc.

    6600 Dumbarton Circle

    Fremont, California 94555

    (650) 752-1300

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

    Copies to:

     

    Laura Berezin

    Asa Henin

    Allison Peth
    Cooley LLP

    1700 Seventh Avenue

    Seattle, WA 98101-1355

    (206) 452-8700

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

    This Registration Statement on Form S-8 is being filed by the Registrant to register 4,258,557 additional shares of Common Stock reserved for issuance under the 2019 Plan and 500,000 additional shares of Common Stock reserved for issuance under the ESPP.

    Pursuant to General Instruction E of Form S-8, the contents of the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on June 20, 2019 (File No. 333-232233), the Registration Statement on Form S-8 filed with the Commission on March 25, 2020 (File No. 333-237386), the Registration Statement on Form S-8 filed with the Commission on May 7, 2020 (File No.  333-238080), the Registration Statement on Form S-8 filed with the Commission on February 25, 2021 (File No. 333-253528), the Registration Statement on Form S-8 filed with the Commission on February 24, 2022 (File No. 333-262998), the Registration Statement on Form S-8 filed with the Commission on February 23, 2023 (File No. 333-269971), the Registration Statement on Form S-8 filed with the Commission on May 15, 2023 (File No.  333-271940), and the Registration Statement on Form S-8 filed with the Commission on February 29, 2024 (File No. 333-277489) are hereby incorporated in this Registration Statement by reference to the extent not replaced hereby.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

    The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act, and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February 27, 2025.

    (b) The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December  31, 2023 from the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 2, 2024.

    (c) The description of the Registrant’s Common Stock filed as Exhibit 4.1 which is contained in a registration statement on Form 8-A filed on June 17, 2019 (File No.  001-38943) under the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Commission on February 25, 2021.

    (d) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    1


    Item 8.

    Exhibits.

     

              Incorporation by Reference

    Exhibit

    Number

      

    Description

       Form    File No.    Exhibit    Filing Date
      4.1    Amended and Restated Certificate of Incorporation of Personalis, Inc.    8-K    001-38943    3.1    6/24/2019
      4.2    Amended and Restated Bylaws of Personalis, Inc.    8-K    001-38943    3.1    10/31/2022
      4.3    Form of common stock certificate of the Registrant.    S-1/A    333-231703    4.1    6/7/2019
      5.1*    Opinion of Cooley LLP.            
     23.1*    Consent of BDO USA, P.C. Independent Registered Public Accounting Firm.            
     23.2*    Consent of Cooley LLP (reference is made to Exhibit 5.1).            
     24.1*    Power of Attorney (reference is made to the signature page hereto).            
     99.1    Personalis, Inc. 2019 Equity Incentive Plan and forms of agreements thereunder.    S-1/A    333-231703    10.2    6/7/2019
     99.2    Personalis, Inc. 2019 Employee Stock Purchase Plan.    S-1/A    333-231703    10.3    6/7/2019
    107*    Filing Fee Table            

     

    *

    Filed herewith.

     

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, State of California, on February 27, 2025.

     

    PERSONALIS, INC.
    By:   /s/ Aaron Tachibana
      Aaron Tachibana
      Chief Financial Officer and Chief Operating Officer
      (Principal Financial and Accounting Officer)

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Christopher Hall and Aaron Tachibana as his or her true and lawful attorneys-in-fact and agents, with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Name and Signature    Title   Date

    /s/ Christopher Hall

    Christopher Hall

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      February 27, 2025

    /s/ Aaron Tachibana

    Aaron Tachibana

      

    Chief Financial Officer and Chief Operating Officer

    (Principal Financial and Accounting Officer)

      February 27, 2025

    /s/ Karin Eastham

    Karin Eastham

       Director   February 27, 2025

    /s/ Olivia Bloom

    Olivia Bloom

       Director   February 27, 2025

    /s/ A. Blaine Bowman

    A. Blaine Bowman

       Director   February 27, 2025

    /s/ Woodrow A. Myers, Jr.

    Woodrow A. Myers, Jr., M.D.

       Director   February 27, 2025

    /s/ Lonnie Shoff

    Lonnie Shoff

       Director   February 27, 2025

    /s/ Kenneth Widder

    Kenneth J. Widder, M.D.

       Director   February 27, 2025

     

     

    3

    Get the next $PSNL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PSNL

    DatePrice TargetRatingAnalyst
    3/17/2025$8.00Buy
    Canaccord Genuity
    2/6/2023$8.00Hold → Buy
    Needham
    2/6/2023Hold → Buy
    Needham
    2/25/2022$30.00 → $24.00Outperform
    Oppenheimer
    2/25/2022$30.00 → $18.00Buy
    Citigroup
    2/25/2022$50.00 → $38.00Buy
    HC Wainwright & Co.
    1/7/2022$27.00 → $23.00Neutral → Buy
    BofA Securities
    11/8/2021$32.00 → $25.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $PSNL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Personalis Reports First Quarter 2025 Financial Results

      Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights. Recent Business Highlights Delivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,441 tests delivered in the fourth quarter of 2024, signifying increasing adoption of Personalis' technology Highlighted compelling performance of NeXT Personal for resectable Stage I-IV colorectal cancer (CRC) in a study

      5/6/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

      100% of resectable Stage I-IV colorectal cancer relapses were detected ahead of imaging, with 87% of those relapses having been detected in the first eight weeks following surgery Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced new interim analysis results of the VICTORI study showing strong performance of its ultra-sensitive NeXT Personal assay in detecting early signs of residual or recurrent colorectal cancer (CRC). The study, led by Dr. Jonathan Loree's team at BC Cancer in Vancouver, Canada, utilized NeXT Personal to look for small traces of circulating tumor DNA (ctDNA) in blood samples from a cohort of 71 patients with resecta

      4/28/25 5:00:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis to Announce First Quarter 2025 Financial Results

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusio

      4/22/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CFO AND COO Tachibana Aaron

      4 - Personalis, Inc. (0001527753) (Issuer)

      3/18/25 4:50:13 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • SEC Form 4 filed by SVP and Chief Legal Officer Moore Stephen Michael

      4 - Personalis, Inc. (0001527753) (Issuer)

      3/18/25 4:46:49 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • SEC Form 4 filed by PRESIDENT AND CEO Hall Christopher M

      4 - Personalis, Inc. (0001527753) (Issuer)

      3/18/25 4:44:44 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Personalis Inc.

      10-Q - Personalis, Inc. (0001527753) (Filer)

      5/6/25 4:24:12 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • SEC Form 8-K filed by Personalis Inc.

      8-K - Personalis, Inc. (0001527753) (Filer)

      5/6/25 4:12:22 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by Personalis Inc.

      EFFECT - Personalis, Inc. (0001527753) (Filer)

      4/4/25 12:15:19 AM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Personalis with a new price target

      Canaccord Genuity initiated coverage of Personalis with a rating of Buy and set a new price target of $8.00

      3/17/25 8:20:27 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis upgraded by Needham with a new price target

      Needham upgraded Personalis from Hold to Buy and set a new price target of $8.00

      2/6/23 9:09:41 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis upgraded by Needham

      Needham upgraded Personalis from Hold to Buy

      2/6/23 7:33:26 AM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Myers Woodrow A Jr bought $16,700 worth of shares (10,000 units at $1.67), increasing direct ownership by 62% to 26,116 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      3/5/24 5:15:53 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Leadership Updates

    Live Leadership Updates

    See more
    • Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

      Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held se

      10/18/23 7:15:00 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • Dr. Kenneth J. Widder Joins Personalis Board of Directors

      Personalis, Inc. (NASDAQ:PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an M.D. from Northwestern University and trained in pathology at Duke University. "We are delighted to ha

      6/13/23 7:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis Announces CEO Retirement and Transition

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West has served in the DNA sequencing field for over forty years, and co-founded Personalis with four Stanford professors in 2011. Effective December 31, 2022, Aaron Tachibana, Personalis Chief Financial Officer, will serve as interim CEO and Christopher Hall, Personalis SVP and Head, Diagnostics Business, will be promoted to President. Mr. West will continue to serve as an advisor to the Board. "We th

      12/14/22 4:02:00 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Personalis Inc.

      SC 13G/A - Personalis, Inc. (0001527753) (Subject)

      8/19/24 6:03:38 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Personalis Inc.

      SC 13G - Personalis, Inc. (0001527753) (Subject)

      7/26/24 12:56:21 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Personalis Inc.

      SC 13D/A - Personalis, Inc. (0001527753) (Subject)

      6/28/24 4:01:17 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Financials

    Live finance-specific insights

    See more
    • Personalis Reports First Quarter 2025 Financial Results

      Clinical test volume of 2,184 increased 52% sequentially Pharma tests and services of $13.6 million increased 39% year-over-year Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights. Recent Business Highlights Delivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,441 tests delivered in the fourth quarter of 2024, signifying increasing adoption of Personalis' technology Highlighted compelling performance of NeXT Personal for resectable Stage I-IV colorectal cancer (CRC) in a study

      5/6/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis to Announce First Quarter 2025 Financial Results

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusio

      4/22/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

      Full year revenue of $84.6 million represents a 15% year-over-year increase Cash balance of $185 million expected to provide runway to cash flow break-even Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business highlights. Recent Business Highlights Delivered 1,441 total molecular tests in the fourth quarter of 2024, an increase of 52% compared with 945 tests delivered in the third quarter of 2024; delivered 3,285 total molecular tests for the full year of 2024 compared with 177 in 2023 Submitted for Medicare coverage in early

      2/27/25 4:01:00 PM ET
      $PSNL
      Medical Specialities
      Health Care